NASDAQ:CLPT - ClearPoint Neuro Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.00
  • Forecasted Upside: 153.07 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$13.83
▼ -0.68 (-4.69%)

This chart shows the closing price for CLPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ClearPoint Neuro Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLPT

Analyst Price Target is $35.00
▲ +153.07% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ClearPoint Neuro in the last 3 months. The average price target is $35.00, with a high forecast of $38.00 and a low forecast of $32.00. The average price target represents a 153.07% upside from the last price of $13.83.

This chart shows the closing price for CLPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in ClearPoint Neuro.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2021B. RileyReiterated RatingBuyMedium
3/18/2021Lake Street CapitalInitiated CoverageBuy$32.00High
2/22/2021B. RileyReiterated RatingBuy$23.00 ➝ $38.00Medium
1/28/2021B. RileyReiterated RatingBuy$8.00Low
1/22/2021B. RileyBoost Price TargetBuy$18.00 ➝ $23.00High
1/12/2021B. RileyBoost Price TargetBuy$16.00 ➝ $18.00Medium
11/11/2020B. RileyBoost Price Target$8.00 ➝ $10.50High
7/17/2020B. RileyInitiated CoverageBuy$8.00High
3/12/2020Brookline Capital ManagementInitiated CoverageBuy$15.00N/A
3/11/2020Brookline Capital ManagementReiterated RatingBuyHigh
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
ClearPoint Neuro logo
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform comprises of ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Irvine, CA.
Read More

Today's Range

Now: $13.83
Low: $13.38
High: $14.28

50 Day Range

MA: $17.18
Low: $13.70
High: $19.62

52 Week Range

Now: $13.83
Low: $9.12
High: $31.29

Volume

246,109 shs

Average Volume

351,442 shs

Market Capitalization

$326.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of ClearPoint Neuro?

The following sell-side analysts have issued reports on ClearPoint Neuro in the last twelve months: B. Riley, Lake Street Capital, and Zacks Investment Research.
View the latest analyst ratings for CLPT.

What is the current price target for ClearPoint Neuro?

2 Wall Street analysts have set twelve-month price targets for ClearPoint Neuro in the last year. Their average twelve-month price target is $35.00, suggesting a possible upside of 153.1%. B. Riley has the highest price target set, predicting CLPT will reach $38.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $32.00 for ClearPoint Neuro in the next year.
View the latest price targets for CLPT.

What is the current consensus analyst rating for ClearPoint Neuro?

ClearPoint Neuro currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLPT will outperform the market and that investors should add to their positions of ClearPoint Neuro.
View the latest ratings for CLPT.

What other companies compete with ClearPoint Neuro?

How do I contact ClearPoint Neuro's investor relations team?

ClearPoint Neuro's physical mailing address is 5 MUSICK, IRVINE CA, 92618. The company's listed phone number is (949) 900-6833 and its investor relations email address is [email protected] The official website for ClearPoint Neuro is www.clearpointneuro.com.